RU94031165A - Use of arylindole-derivatives for psychosis treatment and a method of treatment - Google Patents
Use of arylindole-derivatives for psychosis treatment and a method of treatmentInfo
- Publication number
- RU94031165A RU94031165A RU94031165/14A RU94031165A RU94031165A RU 94031165 A RU94031165 A RU 94031165A RU 94031165/14 A RU94031165/14 A RU 94031165/14A RU 94031165 A RU94031165 A RU 94031165A RU 94031165 A RU94031165 A RU 94031165A
- Authority
- RU
- Russia
- Prior art keywords
- hydrogen
- alkyl
- cycloalkylmethyl
- cycloalkyl
- alkenyl
- Prior art date
Links
- 208000028017 Psychotic disease Diseases 0.000 title claims abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 12
- 239000001257 hydrogen Substances 0.000 claims abstract 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract 9
- 150000002431 hydrogen Chemical class 0.000 claims abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 4
- 229910052799 carbon Chemical group 0.000 claims abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 4
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims abstract 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 4
- 239000001301 oxygen Substances 0.000 claims abstract 4
- 229910052717 sulfur Chemical group 0.000 claims abstract 4
- 239000011593 sulfur Chemical group 0.000 claims abstract 4
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract 2
- 210000004556 brain Anatomy 0.000 claims abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims abstract 2
- 229960003638 dopamine Drugs 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- 239000011737 fluorine Substances 0.000 claims abstract 2
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 2
- 229910052736 halogen Inorganic materials 0.000 claims abstract 2
- 150000002367 halogens Chemical class 0.000 claims abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 2
- 210000002569 neuron Anatomy 0.000 claims abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 2
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 2
- -1 cyan Chemical group 0.000 claims 1
- 230000005284 excitation Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000008925 spontaneous activity Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
FIELD: organic chemistry. SUBSTANCE: product: 6- and/or 2-substituted 1-arylindole-derivative of the general formula (I) where Ar is nonobligatory substituted phenyl or heteroaromatic group; X and X' are hydrogen, halogen, alkyl, alkoxy, hydroxyl, alkylthio, alkylsulfonyl, alkyl- or dialkylamino, cyano, trifluoromethyl or trifluoromethylthio; or X and X' were combined to 5-7-membered carbocyclic ring; Ris hydrogen or lower alkyl at condition that if X - hydrogen or fluorine then Rdoes not hydrogen; Y is nitrogen or carbon; R is hydrogen, alkyl, alkenyl, cycloalkyl or cycloalkylmethyl or R - a substituent of the formula (Ia) or (Iв) where n - whole number = 2, 6; W is oxygen or sulfur; U is nitrogen or carbon; Z is -/CH/-, -CH=CH-, -COCH-,-CSCH- or 1,2-phenylene; V is oxygen, sulfur, CHor NR; Vis -O-R,-S-R,-CHRRor -NRRand R,Rand Rare hydrogen, alkyl, alkenyl, cycloalkyl or cycloalkylmethyl. Synthesized compounds inhibit the spontaneous activity of dopamine neurons excitement in ventricle brain region and can be used for human psychosis treatment. EFFECT: improved method of synthesis, psychosis treatment.
Claims (1)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK912065A DK206591D0 (en) | 1991-12-23 | 1991-12-23 | TREATMENT OF PSYCHOSIS |
| DK2065/91 | 1991-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU94031165A true RU94031165A (en) | 1996-06-20 |
Family
ID=8109829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU94031165/14A RU94031165A (en) | 1991-12-23 | 1992-12-21 | Use of arylindole-derivatives for psychosis treatment and a method of treatment |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0618799A1 (en) |
| JP (1) | JPH07502517A (en) |
| AU (1) | AU668537B2 (en) |
| CA (1) | CA2126571A1 (en) |
| CZ (1) | CZ153994A3 (en) |
| DK (1) | DK206591D0 (en) |
| NO (1) | NO942378L (en) |
| RU (1) | RU94031165A (en) |
| SK (1) | SK75794A3 (en) |
| WO (1) | WO1993012790A1 (en) |
| ZA (1) | ZA9210001B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5554030A (en) * | 1994-06-30 | 1996-09-10 | Minnesota Mining And Manufacturing Company | Method for bonding non-amalgam restorative materials to dental surfaces |
| EP0932407A4 (en) * | 1996-03-25 | 2002-04-24 | Lilly Co Eli | Method for treating migraine pain |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE58370B1 (en) * | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8908085D0 (en) * | 1989-04-11 | 1989-05-24 | Lundbeck & Co As H | New therapeutic use |
| DK158590D0 (en) * | 1990-07-02 | 1990-07-02 | Lundbeck & Co As H | indole derivatives |
| DK238190D0 (en) * | 1990-10-03 | 1990-10-03 | Lundbeck & Co As H | DEPOT DERIVATIVES |
| DK8492D0 (en) * | 1992-01-23 | 1992-01-23 | Lundbeck & Co As H | TREATMENT OF PSYCHOSIS |
-
1991
- 1991-12-23 DK DK912065A patent/DK206591D0/en not_active Application Discontinuation
-
1992
- 1992-12-21 WO PCT/DK1992/000390 patent/WO1993012790A1/en not_active Ceased
- 1992-12-21 CZ CZ941539A patent/CZ153994A3/en unknown
- 1992-12-21 SK SK757-94A patent/SK75794A3/en unknown
- 1992-12-21 AU AU33452/93A patent/AU668537B2/en not_active Ceased
- 1992-12-21 RU RU94031165/14A patent/RU94031165A/en unknown
- 1992-12-21 JP JP5511365A patent/JPH07502517A/en active Pending
- 1992-12-21 EP EP93902096A patent/EP0618799A1/en not_active Ceased
- 1992-12-21 CA CA002126571A patent/CA2126571A1/en not_active Abandoned
- 1992-12-23 ZA ZA9210001A patent/ZA9210001B/en unknown
-
1994
- 1994-06-22 NO NO942378A patent/NO942378L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK206591D0 (en) | 1991-12-23 |
| WO1993012790A1 (en) | 1993-07-08 |
| NO942378L (en) | 1994-06-22 |
| EP0618799A1 (en) | 1994-10-12 |
| AU3345293A (en) | 1993-07-28 |
| NO942378D0 (en) | 1994-06-22 |
| JPH07502517A (en) | 1995-03-16 |
| SK75794A3 (en) | 1995-04-12 |
| CA2126571A1 (en) | 1993-07-08 |
| ZA9210001B (en) | 1994-01-13 |
| CZ153994A3 (en) | 1995-06-14 |
| AU668537B2 (en) | 1996-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU94044671A (en) | Use of nonpeptide antagonists of tachykinin receptors | |
| EP1259487B8 (en) | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | |
| BR9916282A (en) | Compound, use of a compound and method of treatment | |
| BR0012136A (en) | Highly selective norepinephrine reabsorption inhibitors and methods of using them | |
| KR910006225A (en) | Benzoylguanidine, a process for its preparation. Uses thereof as medicaments and medicaments containing the same | |
| RU94045155A (en) | Methods of alzheimer's disease inhibition | |
| ES2143526T3 (en) | DERIVATIVES OF AMIDA THAT HAVE ANTI-HYPERCHOLESTEROLEMIC ACTIVITY, ITS PREPARATION AND ITS THERAPEUTIC USES. | |
| RU94044453A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for seborrhea and acne inhibition | |
| RU94044454A (en) | Inhibitor of autoimmune diseases | |
| RU94044356A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for thrombodulin expression increase to inhibit thrombotic disorder, for protein c activation | |
| ATE398449T1 (en) | USE OF AZETIDINE CARBOXAMIDE DERIVATIVES IN THERAPY | |
| DE69907419D1 (en) | Antitumorwirkstoffe | |
| RU94037246A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for cartilage destruction inhibition | |
| RU94044489A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for myeloperoxidase activity inhibition | |
| RU98119076A (en) | DERIVATIVES OF 2- (3H) -OXASOLONE AND THEIR APPLICATION AS SOX-2 INHIBITORS | |
| RU94045277A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for inhibition of central nervous system disorder in women at postmenopause | |
| NO833900L (en) | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE Naphthalene Derivatives | |
| RU94045271A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for terner's syndrome inhibition | |
| EP0645382A4 (en) | COUMARIN DERIVATIVE AND ITS USE. | |
| RU94045156A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for premature sexual maturation inhibition | |
| RU94031165A (en) | Use of arylindole-derivatives for psychosis treatment and a method of treatment | |
| NO913331L (en) | 4-SUBSTITUTED DIHYDROPYRIDO (4,3-D) PYRIMIDINES FOR TREATMENT OF SKIN DISORDERS. | |
| RU2002105518A (en) | Heterocyclic compounds inhibiting angiogenesis | |
| IL70559A (en) | Carbamoyloxybenzhydrol derivatives,their preparation and pharmaceutical compositions containing them | |
| RU94035658A (en) | Use of 3-arylindole and 3-arylindazole derivatives for psychosis treatment, method of treatment |